share_log

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3：募資說明書
美股SEC公告 ·  09/09 06:05

Moomoo AI 已提取核心訊息

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced on August 30, 2024, that it received a delisting notice from Nasdaq due to its share price falling below the minimum $1.00 bid price for 30 consecutive business days. The company, which is developing treatments for diseases with unmet medical needs, is not eligible for the usual 180-day compliance period to regain compliance due to prior reverse stock splits. Biodexa intends to appeal the delisting decision by requesting a hearing before a Nasdaq Hearings Panel, which will stay any suspension or delisting action until the hearing and any subsequent extension period. The company's securities are currently listed under the symbol 'BDRX' on the NASDAQ Capital Market. Additionally, Biodexa filed a Prospectus Supplement No. 12 to update its registration statement with information from its Form 6-K, which includes a press release about the delisting notice and details of its product pipeline, such as eRapa, tolimidone, and MTX110 for various medical conditions. The company's headquarters are located in Cardiff, UK.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced on August 30, 2024, that it received a delisting notice from Nasdaq due to its share price falling below the minimum $1.00 bid price for 30 consecutive business days. The company, which is developing treatments for diseases with unmet medical needs, is not eligible for the usual 180-day compliance period to regain compliance due to prior reverse stock splits. Biodexa intends to appeal the delisting decision by requesting a hearing before a Nasdaq Hearings Panel, which will stay any suspension or delisting action until the hearing and any subsequent extension period. The company's securities are currently listed under the symbol 'BDRX' on the NASDAQ Capital Market. Additionally, Biodexa filed a Prospectus Supplement No. 12 to update its registration statement with information from its Form 6-K, which includes a press release about the delisting notice and details of its product pipeline, such as eRapa, tolimidone, and MTX110 for various medical conditions. The company's headquarters are located in Cardiff, UK.
生物德沙製藥有限公司是一家處於臨床階段的生物製藥公司，於2024年8月30日宣佈，由於其股價連續30個交易日低於最低1.00美元的買盤價格，收到了納斯達克的除牌通知。該公司正在研發治療存在未滿足醫療需求的疾病的藥物，由於之前進行了逆向拆股並股，該公司無法獲得通常的180天合規期限來恢復合規性。生物德沙打算通過請求納斯達克聽證會的聽證來對除牌決定進行上訴，這將在聽證會及任何後續延期期間暫停任何暫停或除牌行動。該公司的證券目前在納斯達克資本市場上以「BDRX」符號列出。此外，生物德沙提交了《招股說明書補充公告12號》，以從其6-k表格中獲取的信息更新其註冊聲明，其中包括關於除牌通知的新聞稿和其產品管道的詳細信息，如eRapa、tolimidone和MTX110，用於各種醫療狀況。該公司總部位於英國加的夫。
生物德沙製藥有限公司是一家處於臨床階段的生物製藥公司，於2024年8月30日宣佈，由於其股價連續30個交易日低於最低1.00美元的買盤價格，收到了納斯達克的除牌通知。該公司正在研發治療存在未滿足醫療需求的疾病的藥物，由於之前進行了逆向拆股並股，該公司無法獲得通常的180天合規期限來恢復合規性。生物德沙打算通過請求納斯達克聽證會的聽證來對除牌決定進行上訴，這將在聽證會及任何後續延期期間暫停任何暫停或除牌行動。該公司的證券目前在納斯達克資本市場上以「BDRX」符號列出。此外，生物德沙提交了《招股說明書補充公告12號》，以從其6-k表格中獲取的信息更新其註冊聲明，其中包括關於除牌通知的新聞稿和其產品管道的詳細信息，如eRapa、tolimidone和MTX110，用於各種醫療狀況。該公司總部位於英國加的夫。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間